ADAM9 and prostate carcinoma: To assess the growth difference between ADAM9-proficient and ADAM9-deficient cancer cells in bone, the primary metastatic site for prostate cancer, luciferase-tagged PC3shGFP and PC3shADAM9 were intratibially injected into the same nude mouse but at different legs (Fig. 2a, n = 10).